131 related articles for article (PubMed ID: 7038420)
21. Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid.
Cersosimo RJ; Bromer R; Licciardello JT; Hong WK
Pharmacotherapy; 1983; 3(5):259-74. PubMed ID: 6359081
[TBL] [Abstract][Full Text] [Related]
22. Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas.
Bayssas M; Gouveia J; Ribaud P; Musset M; de Vassal F; Pico JL; de Luca L; Misset JL; Machover D; Belpomme D; Schwarzenberg L; Jasmin C; Hayat M; Mathé G
Cancer Chemother Pharmacol; 1979; 2(4):247-55. PubMed ID: 287569
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of vindesine in patients with metastatic breast cancer.
Cobleigh MA; Williams SD; Einhorn LH
Cancer Treat Rep; 1981; 65(7-8):659-63. PubMed ID: 7248983
[TBL] [Abstract][Full Text] [Related]
24. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
Gasparini G; Caffo O; Barni S; Frontini L; Testolin A; Guglielmi RB; Ambrosini G
J Clin Oncol; 1994 Oct; 12(10):2094-101. PubMed ID: 7931479
[TBL] [Abstract][Full Text] [Related]
25. An EORTC phase II study of vindesine in advanced prostate cancer.
Jones WG; Fosså SD; Denis L; Coninx P; Glashan RW; Akdas A; De Pauw M
Eur J Cancer Clin Oncol; 1983 May; 19(5):583-8. PubMed ID: 6683629
[TBL] [Abstract][Full Text] [Related]
26. Vindesine in head and neck cancer. A Southwest Oncology Group Phase II pilot study.
Haas CD; Fabian CJ; Stephens RL; Kish J
Invest New Drugs; 1983; 1(4):339-40. PubMed ID: 6678881
[TBL] [Abstract][Full Text] [Related]
27. Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study.
Quagliana JM; Stephens RL; Baker LH; Costanzi JJ
J Clin Oncol; 1984 Apr; 2(4):316-9. PubMed ID: 6707719
[TBL] [Abstract][Full Text] [Related]
28. Treatment of acute lymphoblastic leukemia in adults with combination chemotherapy incorporating vindesine and prednisolone.
Saito Y; Uzuka Y
Tohoku J Exp Med; 1983 Apr; 139(4):421-2. PubMed ID: 6575488
[TBL] [Abstract][Full Text] [Related]
29. [A late phase-II trial comparing KW-2307 with vindesine in non-small cell lung cancer (1). Lung cancer section in KW-2307 Study Group].
Furuse K; Yamori S; Negoro S; Fukuoka M; Takada Y; Nakai Y; Ikegami H; Fujii M; Nakajima S; Katakami N
Gan To Kagaku Ryoho; 1995 Jan; 22(1):67-76. PubMed ID: 7826080
[TBL] [Abstract][Full Text] [Related]
30. Initial clinical studies of vindesine.
Valdivieso M; Richman S; Burgess AM; Bodey GP; Freireich EJ
Cancer Treat Rep; 1981; 65(9-10):873-5. PubMed ID: 6268296
[TBL] [Abstract][Full Text] [Related]
31. [Therapy of the blast crisis in chronic myeloid leukemia. Results of a phase II study with vindesine].
Hellriegel KP
Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(5):699-706. PubMed ID: 6172337
[No Abstract] [Full Text] [Related]
32. [Vindesine in oral cancers].
Szpirglas H; Marneur M; Vaillant JM
Presse Med; 1985 Feb; 14(7):405-7. PubMed ID: 3157128
[TBL] [Abstract][Full Text] [Related]
33. Treatment of esophageal cancer with vindesine: an open trial.
Bezwoda WR; Derman DP; Weaving A; Nissenbaum M
Cancer Treat Rep; 1984 May; 68(5):783-5. PubMed ID: 6722833
[TBL] [Abstract][Full Text] [Related]
34. [Leukaemias and lymphomas treatment by vindesine. Result of a phase II trial in terms of remission induction (author's transl)].
Marthé G; Misset JL; de Vassal F; Hayat M; Gouveia J; Machover D; Belpomme D; Schwarzenberg L; Ribaud P; Pico JL; Musset M; Jasmin C; de Luca L
Nouv Presse Med; 1978 Feb; 7(7):525-8. PubMed ID: 273888
[TBL] [Abstract][Full Text] [Related]
35. A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study.
Vats T; Buchanan G; Mehta P; Ragab A; Hvizdale E; Nitschke R; Link M; Beardsley GP; Maybee D; Krischer J
Invest New Drugs; 1992 Aug; 10(3):231-4. PubMed ID: 1428733
[TBL] [Abstract][Full Text] [Related]
36. A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma.
Yau JC; Yap YY; Buzdar AU; Hortobagyi GN; Bodey GP; Blumenschein GR
Cancer; 1985 Jan; 55(2):337-40. PubMed ID: 3880657
[TBL] [Abstract][Full Text] [Related]
37. Vindesine for metastatic malignant melanoma. A phase II trial.
Nelimark RA; Peterson BA; Vosika GJ; Conroy JA
Am J Clin Oncol; 1983 Oct; 6(5):561-4. PubMed ID: 6613921
[TBL] [Abstract][Full Text] [Related]
38. A phase II trail of vindesine in patients with refractory small-cell carcinoma of the lung.
Fuks JZ; Aisner J; Carney DN; Van Echo DA; Ostrow SS; Ihde DC; Wiernik PH
Am J Clin Oncol; 1982 Feb; 5(1):49-52. PubMed ID: 6282108
[TBL] [Abstract][Full Text] [Related]
39. A multicentre phase II trial of vindesine in malignant melanoma.
Carmichael J; Atkinson RJ; Calman KC; Mackie RM; Naysmith AM; Smyth JF
Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1293-5. PubMed ID: 6891927
[TBL] [Abstract][Full Text] [Related]
40. Vindesine in advanced breast cancer, lymphoma and melanoma. A Colorado Clinical Oncology Group study.
DiBella NJ; Berris R; Garfield D; Fink K; Speer J; Sakamoto A
Invest New Drugs; 1984; 2(3):323-8. PubMed ID: 6511238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
